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Abstract objectives To examine the association between aflatoxin (AF) exposure during pregnancy and rate
of gestational weight gain (GWG) in a sample of pregnant women of mixed HIV status in Gulu,
northern Uganda.
methods 403 pregnant women were included (133 HIV-infected on antiretroviral therapy (ART),
270 HIV-uninfected). Women’s weight, height and socio-demographic characteristics were collected
at baseline (~19 weeks’ gestation); weight was assessed at each follow-up visit. Serum was collected
at baseline and tested for aflatoxin B1-lysine adduct (AFB-lys) levels using high-performance liquid
chromatography (HPLC). Linear mixed-effects models were used to examine the association between
AFB-lys levels and rate of GWG.
results AFB-lys levels (detected in 98.3% of samples) were higher among HIV-infected pregnant
women than HIV-uninfected pregnant women [median (interquartile range): 4.8 (2.0, 15.0) vs. 3.5
(1.6, 6.1) pg/mg of albumin, P < 0.0001]. Adjusting for HIV status, a one-log increase in aflatoxin
levels was associated with a 16.2 g per week lower rate of GWG (P = 0.028). The association
between AFB-lys and the rate of GWG was stronger and significant only among HIV-infected women
on ART [25.7 g per week per log (AFB-lys), P = 0.009 for HIV-infected women vs. 7.5 g per
week per log (AFB-lys), P = 0.422 for HIV-uninfected women].
conclusions Pregnant women with higher levels of AF exposure had lower rates of GWG. The
association was stronger for HIV-infected women on ART, suggesting increased risk.
keywords aflatoxin, HIV, pregnancy outcomes, Uganda
Sustainable Development Goals (SDGs): SDG 3 (good health and well-being), SDG 10 (reduced
inequalities), SDG 17 (partnerships for the goals)
Introduction
Gestational weight gain (GWG), the change in a pregnant
woman’s weight between the beginning and the end of
pregnancy, is a basic indicator of maternal and foetal
health during the prenatal period [1]. Inadequate GWG is
a recognised risk factor for infants being born preterm
(<37 weeks gestation) and/or low birthweight (LBW)
(<2500 g) particularly in low- and middle-income
countries (LMICs) [2, 3]. While suboptimal GWG is
thought to reflect poor nutritional status, both before con-
ception and during pregnancy, other mechanisms underly-
ing inadequate GWG remain poorly understood [4–6].
Aflatoxins (AF) are naturally occurring, toxic metabo-
lites of Aspergillus moulds, widespread in the global sta-
ple food supply (e.g. rice, corn (maize), cassava, nuts,
peanuts (groundnuts), chilies and spices among many
others), notably in LMICs where it is estimated that
4.5 billion people are chronically exposed [7]. Across
animal and human models, AF exposure has been*Joint first authors.
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shown to inhibit protein synthesis [8]; promote an
inflammatory response [9, 10]; and underlie a number
of carcinogenic, teratogenic and immunotoxic health
effects [11]. Aflatoxin B1 (AFB1), the most prevalent
and toxic variety of AFs [12, 13], is a known potent
class 1 human liver carcinogen and is synergistic with
hepatitis B and C infections in causing liver cancer [14,
15]. Furthermore, in several studies, AFB1 has been
linked to poor linear growth among children in LMICs
[16–18], though the quality of evidence for this associa-
tion remains low [19].
It is established that AFs are capable of crossing the
placental barrier during pregnancy [20, 21] and are
toxic to rapidly growing normal cells, as are found in
utero and in infancy [22]. Animal studies consistently
demonstrate significant adverse effects (i.e. decreased
foetal weight, crown–rump length and organ weight) of
AF exposure on foetal growth [23–26]. A recent study
found the mutagenic effect of in utero AF exposure in
14-day-old C57BL/6 mouse embryos was 20-fold greater
than in parallel-dosed adult mice [27]. While there are
relatively few human studies examining the relationship
between AF exposure and foetal outcomes, a limited
number of studies have demonstrated an association
between maternal exposure and lower infant birth-
weight, small for gestational age [28–32] and subsequent
stunted growth [33].
Proposed mechanisms by which maternal AF exposure
could cause adverse foetal outcomes, including decreased
GWG, include (i) induction of environmental enteric
dysfunction (EED) characterised by intestinal inflamma-
tion, impaired barrier function and systemic immune
activation; (ii) upregulation of pro-inflammatory cytoki-
nes and/or downregulation of anti-inflammatory cytoki-
nes; (iii) toxic effects on maternal and foetal organs
causing systemic immune activation and impaired pla-
cental and foetal development; and (iv) impairment of
the insulin-like factor growth axis [34]. There is evi-
dence to suggest that maternal HIV infection may exac-
erbate this relationship. In Ghana, HIV infection was
found to be associated with higher AF levels [35, 36],
speculatively due to HIV’s ability to impair liver func-
tion resulting in a decreased ability to detoxify toxic
metabolites, including AF [37]. Furthermore, high AF
levels were shown to accentuate some HIV-associated
changes in T-cell phenotypes and in B cells in HIV-in-
fected individuals [38].
To date, we are aware of no studies which have exam-
ined the effects of AF exposure on maternal GWG, both
in the general population and in those with HIV. The pri-
mary objective of this study was to examine the associa-
tion between aflatoxin exposure during pregnancy
(assessed via serum levels of the AFB-lys adduct at
~19 weeks of gestation) and the rate of GWG in pregnant
women of mixed HIV status in Gulu, northern Uganda.
Methods
Study design
Data for this study were collected from 2012 to 2013 as
part of the Prenatal Nutrition and Psychosocial Health
Outcomes (PreNAPs) study. PreNAPs was an observa-
tional, longitudinal cohort study designed to explore rela-
tionships among food access, nutritional and
psychosocial exposures, and several physical and mental
health outcomes in a sample of 403 HIV-infected
(n = 133) and HIV-uninfected (n = 270) pregnant women
in Gulu, northern Uganda. The study was approved by
Cornell University’s Institutional Review Board (IRB),
Gulu University’s Institutional Review Committee and
the Uganda National Council for Science and Technology
(UNCST). Written informed consent was obtained from
all participants prior to enrolment. The parent study was
registered at ClinicalTrials.gov as NCT02922829.
PreNAPs methodology (i.e. recruitment process, inclu-
sion and exclusion criteria, response rates, and reasons for
refusal to participate) has been previously reported [39,
40]. Briefly, pregnant women were recruited from the
antenatal clinic (ANC) of Gulu Regional Referral Hospital
(GRRH; i.e. Gulu Hospital), located in Gulu, northern
Uganda. HIV-infected and HIV-uninfected pregnant
women who presented at the ANC between 10- and 26-
week gestation (assessed according to women’s recall of
the first date of their last menstrual period), resided within
30 km of GRRH and had a known HIV status were eligi-
ble to participate in PreNAPs. Women whose HIV status
was unknown were excluded from participation.
Of the 415 pregnant women asked to participate in
PreNAPs, 405 accepted, while 10 refused citing lack of
time. Of the 405 participating women, complete data on
all the variables of interest for this analysis were available
for 403 women. In PreNAPs, HIV-infected women were
oversampled in order to achieve a minimum ratio of 1
HIV-infected: 2 HIV-uninfected participants. The sample
size for PreNAPs was designed to provide 80% power to
detect a 50-g difference in weight gain between HIV-in-
fected and HIV-uninfected women at a 5% level of sig-
nificance and accounting for a 10% loss to follow-up.
Participation
Women in PreNAPs were followed monthly throughout
their pregnancy (mean  SD prenatal visits per woman:
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5.0  1.1). Women were tested for HIV at the ANC of
GRRH per Government of Uganda (GoU) guidelines
[41]. All HIV-infected pregnant women were participat-
ing in a GoU ART programme to prevent mother-to-child
transmission of HIV. Antiretroviral drugs were provided
to all HIV-infected pregnant women following the GoU
[41] and WHO [42] guidelines.
At enrolment, socio-demographic data were collected
for all women including age, parity (nulliparous vs.
other), marital status (separated, divorced or widowed vs.
other) and education level (primary level or lower vs.
higher than primary level). Maternal height and weight
were measured at enrolment (Seca 206 for height; Seca
874 for weight; Seca North America, Chino, CA, USA).
Weight was re-assessed at all follow-up visits. Gestational
age of the index pregnancy was determined using
women’s recall of the first date of their last menstrual
period. Rate of GWG was calculated by dividing the dif-
ference of maternal weight between the last and first
monthly visit by the corresponding difference of gesta-
tional weeks. Dietary diversity was assessed using the
Minimum Dietary Diversity for Women (MDD-W) indi-
cator [43]. Finally, women were asked about possession
of 20 household assets contained in the socio-economic
module of the 2009–2010 Uganda National Panel Survey
Questionnaire [44]. An asset index was generated using
principal components analysis methodology [45].
Analysis of aflatoxin exposure levels
Serum samples were temporarily stored at 20 °C in Gulu,
northern Uganda, and then transferred to Kampala,
Uganda, where they were stored at 80 °C. Samples were
then shipped to the laboratory at the University of Georgia,
Athens, GA, USA, for analysis. AF exposure was assessed
via serum levels of the AFB-lys adduct using previously
described high-performance liquid chromatography
(HPLC)-fluorescence methods [46, 47]. This included mea-
surement of albumin and total protein concentrations for
each sample, digestion with protease to release amino acids,
concentration and purification of the AFB-lysine adduct,
and finally separation and quantification by HPLC.
GIS cluster and outlier analysis
Household geographic coordinates were obtained for 150
women in the sample. Women’s households were then
mapped using geographic information system (GIS) soft-
ware (ArcGIS, Esri, Redlands, CA, USA) according to
HIV status (infected vs. uninfected) as well as serum
AFB-lys level. AF exposure data were grouped into five
ranges of values determined by the natural breaks (jenks)
classification method [48]. The Anselin Local Moran’s I
statistic tool [49] was used to determine whether there
were statistically significant hot spots, cold spots and/or
cluster outliers of HIV infection or AF levels using an
inverse distance relationship.
Statistical analysis
The main objective of this study was to determine the
effect of AF exposure on the rate of GWG in a sample of
pregnant women of mixed HIV status. Due to their
skewed distribution, AFB-lys levels were log-transformed
prior to analyses. Baseline characteristics for mothers
were calculated and are presented as mean  SD or n
(%). Student’s t-tests were used to compare baseline char-
acters between HIV-infected and HIV-uninfected women.
Associations between AFB-lys levels and baseline charac-
teristics were assessed using either Spearman’s correlation
coefficients in the case of continuous variables or Mann–
Whitney tests in the case of categorical variables.
Linear mixed-effects models were used to determine
the unadjusted and HIV status-adjusted differences in
the rate of GWG per unit increase in baseline log AFB-
lys levels. Thereafter, separate models were fit for HIV-
infected women and HIV-uninfected women to examine
whether the effect of AFs on the rate of GWG differed
in the two study groups. Data were analysed using
Stata 15 software (StataCorp, College Station, TX,




Baseline characteristics for women enrolled in the study
and their non-parametric associations with AFB-lys levels
are presented in Table 1. At enrolment, women were
~25 years old, ~19 weeks’ pregnant and weighed ~61 kg.
The majority were previously pregnant (~76%), married
or cohabitating (~86%), and residing in a peri-urban resi-
dence (~80%).
At baseline, HIV-infected women in the sample were sig-
nificantly different from HIV-uninfected women with
respect to mean age (25.8 vs. 24.1 years, P = 0.001), asset
score (3.6 vs. 4.5, P < 0.001), diet diversity score (MDD-
W) (3.8 vs. 4.2, P = 0.003) and gestational age (18.6 vs.
19.8 weeks, P = 0.007). Additionally, HIV-infected women
in the sample were less likely to be married or cohabitating
(76.7% vs. 90.7%, P < 0.001) and less educated (secondary
education or higher: 35.3% vs. 50.0%, P = 0.005); they
were more likely to have previously been pregnant
© 2020 The Authors Tropical Medicine & International Health Published by John Wiley & Sons Ltd 1147
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(multigravida: 85.0% vs. 71.1%, P = 0.002) and to have
been abducted in the past (24.1% vs. 13.7%, P = 0.009).
In unadjusted non-parametric analyses, AFB-lys levels
were significantly associated with several baseline charac-
teristics including HIV infection (U = 3.2, P = 0.001),
asset score (q = 0.15, P = 0.003) and STI history
(U = 2.4, P = 0.02).
AFB-lys levels
AFB-lys levels were detected in 98.5% of samples [me-
dian: 3.7 pg/mg albumin (range: 0.1–401.5 pg/mg
albumin, interquartile range (IQR): 1.7–7.9 pg/mg albu-
min)]. The arithmetic mean AFB-lys level was 16.6 pg/mg
albumin (95% confidence interval (CI): 11.6–21.6 pg/mg
albumin), and the geometric mean AFB-lys level was
4.2 pg/mg albumin (95% CI: 3.6-4.8 pg/mg albumin).
Figure 1 shows the distribution of AFB-lys levels for
HIV-uninfected women compared with HIV-infected
women. AFB-lys levels were significantly higher among
HIV-infected women compared with HIV-uninfected
women [median (IQR): 4.8 (2.0–15.0) vs. 3.5 (1.6,
6.1) pg/mg albumin, P = 0.001].
Association between AF Exposure and Rate of GWG
Table 2 shows the differences in the rate of GWG per
one-log increase in AFB-lys levels using unadjusted and
adjusted linear mixed-effects models. Adjusting for HIV
status, a one-log increase in AFB-lys was associated with
a 16.2 g per week lower rate of GWG (P = 0.028). Fur-
thermore, as shown in Figure 2, a one-log increase in
AFB-lys was associated with a larger rate of GWG in
HIV-infected women compared with HIV-uninfected
women. For every one-log increase in AFB-lys level, the
rate of GWG in HIV-infected women decreased by
Table 1 Baseline characteristics and their non-parametric associ-






U or Spearman’s q,
P-value‡
HIV status at recruitment
HIV-infected 133 (33%) U = 3.2, 0.001*
Gestational age and anthropometric factors
Gestational age
(weeks)
19.4  3.9 q = 0.03, 0.559
Weight (kg) 60.9  8.5 q = 0.06, 0.257
Height (cm) 163.2  6.0 q = 0.00, 0.949
Body mass index
(BMI, kg/m2)
18.6  2.4 q = 0.06, 0.249
Socio-demographics
Age (years) 24.7  5.1 q = 0.01, 0.883
Asset score 4.2  2.0 q = 0.15, 0.003*
Diet diversity score
(MDD-W)
4.1  1.2 q = 0.03, 0.510
Nulliparous 124 (30.8%) U = 0.5, 0.650
Multigravida 305 (75.7%) U = 0.4, 0.678
Secondary education
or higher
182 (45.2%) U = 1.9, 0.061
Married or cohabiting 347 (86.1%) U = 1.8, 0.074
Contextual factors
Peri-urban residence 323 (80.2%) U = 0.4, 0.652
Ever lived in an IDP
camp
208 (51.6%) U = 1.1, 0.285
Ever been abducted 69 (17.1%) U = 2.5, 0.011*
STI history
History of any STI 48 (11.9%) U = 2.4, 0.020*
HIV, human immunodeficiency virus; IDP, internally displaced
person; MDD-W, minimum dietary diversity for women; STI,
sexually transmitted infection.
†Values are mean  SD or n (%).
‡Testing the unadjusted non-parametric association between
serum AFB-lysine levels and each of the different continuous



















Figure 1 AFB-lysine levels by HIV status for 403 women in
Gulu, northern Uganda.
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25.7 g per week (P = 0.009) compared with 7.5 g per
week for HIV-uninfected women (P = 0.422).
GIS results
No statistically significant hot spots, cold spots and/or
cluster outliers were observed for either HIV-infected or
HIV-uninfected women (Figure 3). Two statistically sig-
nificant individual high outliers were observed for level of
AF exposure, both of whom were HIV-infected women
(Figure 4).
Discussion
In this study of 403 pregnant women of mixed HIV sta-
tus in northern Uganda, we examined the association
between AF exposure during pregnancy and rate of
GWG. AF exposure (as determined by a validated and
reliable exposure biomarker, AFB-lys), in this population,
was nearly universal (detected in ~98% of samples) and
ranged widely from 0.1 to 401.5 pg/mg albumin. This
highly skewed distribution is consistent with those from
another recent study, which found that 100% of samples
from 220 HIV-negative pregnant Ugandan women had
detectable AFB1 levels ranging from 0.71 to 95.60 pg/mg
albumin [31]. Notably, however, a number of women in
this study had alarmingly high levels of AF exposure with
16 women having AFB-lys levels over 100 pg/mg albumin
(15 of 16 were in the HIV-infected group). For compar-
ison purposes, Table S1 shows the reported levels of AF
exposure from previous studies of pregnant women and
infants. Standardised levels of exposure were calculated
based on previously published conversion factors [50].
Furthermore, in this study we observed significantly
higher AF exposure levels among HIV-infected women
compared with HIV-uninfected women. Using GIS, we
tested the hypothesis that HIV-infected women, perhaps
because of stigma or poverty, live in areas of Gulu where
the markets sell food that is significantly more contami-
nated with AFs. We found almost no indication of spatial
clustering in these analyses, suggesting this was not the
case. Therefore, given our findings, we surmise that HIV
infection in and of itself, or being treated for HIV with
Table 2 Linear mixed-effects models to determine the unadjusted and covariate-adjusted differences in the rate of gestational weight
gain (GWG) per one-log increase in AFB-lysine levels for 403 women in Gulu, northern Uganda
Model parameter Unadjusted model Adjusted model†,‡
Constant (b0), starting weight 59.0  0.6 kg 58.5  0.7 kg
Effect of the time variable (gestational age; b1), the rate of GWG 428.5  24.9 g per week
(<0.001)*
442.4  24.6 g per week
(<0.001)*
Effect of the quadratic term of the time variable (gestational age
squared; b2)
4.1  0.7 g per week2
(<0.001)*
4.1  0.7 g per week2
(<0.001)*
Effect of the AFB1 exposure (b3) on starting weight 0.2  0.3 kg (NS) 0.4  0.3 kg (NS)
Effect of exposure on the effect of the time variable (b4), differences in
the rate of GWG
()20.4  7.1 g per week
(0.004)*
()16.2  7.4 g per week
(0.028)*
Effect of exposure on the quadratic term of time variable (b5) Not modelled Not modelled
†Adjusted for HIV status (infected vs. uninfected); that is, the only variable associated with baseline AFB-lysine levels as well as GWG.





























Figure 2 Association between a one-log increase in AFB-lysine
levels and rate of gestational weight gain (GWG) during the sec-
ond and third trimesters for 403 pregnant women in Gulu,
northern Uganda.
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ARTs, may put pregnant women at risk of having higher
AFB-lys levels.
Because both AF exposure and HIV are known to
cause immune suppression [51, 52], a synergistic relation-
ship between the two may exist [53]. In a cross-sectional
study of 314 (155 HIV-infected, 159 HIV-uninfected)
Ghanaian participants, Jolly et al. [35] observed signifi-
cantly higher AFB-albumin levels among HIV-infected
participants (mean  SD: 1.06  0.60 pmol/mg albumin)
compared with HIV-uninfected participants (mean  SD:
0.91  0.46 pmol/mg albumin). In a subsequent cross-
sectional study of 314 antiretroviral-na€ıve, HIV-positive
Ghanaian participants with median CD4 count of 574
cells/ll blood (mean  SD = 630  277 cells/ll blood),
it was observed that HIV viral load increased as AFB-al-
bumin levels increased. In the study, ‘high’ viral load was
2.3 times more likely among participants in the third
AFB-albumin quartile (95% CI: 1.13, 4.51), and 2.9
times more likely among participants in the fourth AFB-
albumin quartile (95% CI: 1.41, 5.88), compared to par-
ticipants in the first quartile [36].
Results from these studies suggest that HIV-infected,
untreated individuals are more likely to have higher AF
exposure levels than HIV-uninfected individuals. Our
study was conducted in a group of HIV-infected women
taking a first-line ART regimen. Examining viral load
suppression data from all samples from the Gulu hub
(August 2014–June 2019) from women receiving first-line
therapy in pregnancy, 92.3% of 1385 tested samples
showed viral suppression [54]. While we do not have
individual viral suppression data from the women
enrolled in this study, we may reasonably infer (since
Figure 3 Household locations for HIV-infected and HIV-uninfected pregnant women (n = 150) in Gulu, northern Uganda. The Anse-
lin Local Moran’s I statistic tool was used to determine whether there were statistically significantly hot spots, cold spots and/or cluster
outliers using an inverse distance relationship. No statistically significant findings were observed for either HIV-infected or HIV-unin-
fected women. [Colour figure can be viewed at wileyonlinelibrary.com]
1150 © 2020 The Authors Tropical Medicine & International Health Published by John Wiley & Sons Ltd
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first-line therapy has not changed) that the women with
HIV in this study would have received therapy that led to
viral suppression in approximately 92.3% of pregnant
recipients seen at the Gulu regional HIV facilities.
We note that the connection between HIV infection
and higher AFB-lys levels is not well understood; how-
ever, it may speculatively be due to HIV’s ability to
impair liver function resulting in a decreased ability to
detoxify toxic metabolites, including AF [37]. Further-
more, in addition to the virus itself, ARVs may also play
a role. To date, ARVs have been linked to various liver
diseases, including hepatotoxicity and idiosyncratic liver
injury, which may also contribute to the accumulation of
AFB-lys in the bloodstream [55]. Overall, AFs may act in
synergy with both HIV and ARTs to damage liver func-
tion and ultimately increase exposure levels.
Finally, in this study we observed that the rate of
GWG was lower among pregnant women with higher
AFB-lys levels. This association was stronger and signifi-
cant only among HIV-infected women. The results from
our study are consistent with several previous studies,
which have demonstrated a link between AF exposure
during pregnancy and adverse foetal outcomes, particu-
larly LBW, for which inadequate GWG is a risk factor.
In a cross-sectional study of 785 pregnant Ghanaian
women with unreported HIV status, Shuaib et al. [32]
observed that participants in the highest AFB-albumin
quartile were more likely to have infants born LBW (OR:
Figure 4 AFB-lysine levels for HIV-infected and HIV-uninfected pregnant women (n = 150) in Gulu, northern Uganda. Exposure data
were grouped into 5 ranges of values determined by the natural breaks (jenks) classification method. The Anselin Local Moran’s I
statistic tool was used to determine whether there were statistically significantly hot spots, cold spots and/or cluster outliers using an
inverse distance relationship. Two statistically significant high outliers were observed. [Colour figure can be viewed at wileyonlinelibra
ry.com]
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2.09, 95% CI: 1.19–3.68). Likewise, in a prospective
cohort study of 220 HIV-uninfected pregnant Ugandan
women, Lauer et al. [31] observed that maternal AF
exposure assessed at ~18 weeks’ gestation was associated
with infants born with lower birthweight (b: 0.07, 95%
CI: 0.13, 0.003) and smaller head circumference (b:
0.26, 95% CI: 0.49, 0.02).
While these studies have examined the relationship
between AF exposure and infant birth outcomes, as far
as we are aware, our study is the first to look at the
impacts of AF exposure on maternal pregnancy out-
comes, that is GWG, and to demonstrate that the asso-
ciation between AF exposure and adverse foetal
outcomes may, in fact, be stronger for HIV-infected
women on ARTs compared with HIV-uninfected
women. There are, however, several limitations worthy
of mention. Notably, gestation was assessed according
to women’s recall of the first date of their last men-
strual period, which is subject to error due to factors
such as recall bias, irregular menses and individual vari-
ation in menstrual cycle length [56]. Furthermore, as
this was an observational cohort study which prospec-
tively assessed observed outcomes with a relatively small
samples size, we have limited ability to draw conclu-
sions regarding causality or the directionality of the
relationships among AF exposure, HIV and ARTs.
However, given the widespread AF exposure, large num-
bers of HIV-infected individuals on ARTs and high rates
of infants born LBW, further studies examining these
relationships are warranted.
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